Immune Discovery & Modeling Service (IDMS)

Overview

Jaap Jan Boelens

Director

Kinga Hosszu

Director

Devin McAvoy

Research Laboratory Manager

Patient Monitoring and Predictive Modeling for Personalized Medicine

The IDMS is a collaborative immuno-oncology service laboratory that performs disease-relevant immune biomarker analysis for longitudinal studies, research arms of clinical trials, as well as other research projects.

Click below to find detailed information about our team and services.

Immune Discovery & Modeling Service (IDMS)

Publications

Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, Russo D, Auclair R, Fitzgerald L, Cadzin B, Wang X, Sikder D, Senechal B, Bermudez VP, Purdon TJ, Hosszu K, McAvoy DP, Farzana T, Mead E, Wilcox JA, Santomasso BD, Shah GL, Shah UA, Korde N, Lesokhin A, Tan CR, Hultcrantz M, Hassoun H, Roshal M, Sen F, Dogan A, Landgren O, Giralt SA, Park JH, Usmani SZ, Rivière I, Brentjens RJ, Smith EL. GPRC5D-Targeted CAR T Cells for Myeloma. N Engl J Med. 2022 Sep 29;387(13):1196-1206. doi: 10.1056/NEJMoa2209900. PMID: 36170501.

Shah UA, Maclachlan KH, Derkach A, Salcedo M, Barnett K, Caple J, Blaslov J, Tran L, Ciardiello A, Burge M, Shekarkhand T, Adintori P, Cross J, Pianko MJ, Hosszu K, McAvoy D, Mailankody S, Korde N, Hultcrantz M, Hassoun H, Tan CR, Lu SX, Patel D, Diamond B, Shah G, Scordo M, Lahoud O, Chung DJ, Landau H, Usmani SZ, Giralt S, Taur Y, Landgren CO, Block G, Block T, Peled JU, van den Brink MRM, Lesokhin AM. Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets. Clin Cancer Res. 2022 Dec 1;28(23):5149-5155. doi: 10.1158/1078-0432.CCR-22-0723. PMID: 36170461; PMCID: PMC9722533.

de Koning C, Prockop S, van Roessel I, Kernan N, Klein E, Langenhorst J, Szanto C, Belderbos M, Bierings M, Boulad F, Bresters D, Cancio M, Curran K, Kollen W, O’Reilly R, Scaradavou A, Spitzer B, Versluijs B, Huitema A, Lindemans C, Nierkens S, Boelens JJ. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. Blood. 2021 Feb 11;137(6):848-855. doi: 10.1182/blood.2020007905. PMID: 33150379; PMCID: PMC7986048.

View All Publications